A phase I trial of allogeneic Tumour-activated natural killer lymphocytes after low dose TBI and fludarabine for the treatment of selected patients with acute myeloid leukaemia.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Dec 2011 Favorable final results were presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH-2011), according to a Coronado Biosciences media release.
15 Nov 2011 Final results will be presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, according to a Coronado Biosciences media release.
12 Oct 2011 United Kingdom Clinical Research Network reports accrual to date changed from 26% to 100%.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com